Hotline:
+ 49 (0) 2204 2918806
Manufacturer: GlobalData

Regeneron Pharmaceuticals, Inc. (REGN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

NULL
SKU:GDPH81628D / 163489
Publication Date:30.01.2013
Language version:English
Format:PDF
Report Type:Marktstudie
Lieferzeit:2-3 Tage
Nr of pages:151 pages
Edition:0
Rating:Für diese Studie liegt keine Bewertung vor.
$250.00   *
* Click here to switch the currency you want to pay in.
Screenshots
Regeneron Pharmaceuticals, Inc. (REGN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
More about this report
Table of Contents
Other relevant reports
Our guarantee
 

Numbers and facts for this report



- Financial Deals - Analysis of the company's financial deals including M&A, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as M&A, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.


Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

Content of the report

Regeneron Pharmaceuticals, Inc. (Regeneron) is a biopharmaceutical company that discovers, develops, manufactures pharmaceutical products for the treatment of serious ailments. The company's product portfolio covers varied therapeutic areas including inflammation and immune diseases, bone and cartilage, pain, cardiovascular diseases, oncology and angiogenesis, ophthalmology, metabolic and related diseases, muscle diseases and disorders. Currently it has two marketed products, Eylea (aflibercept) and Arcalyst (rilonacept) and 13 products in various stages of clinical development. Arcalyst is indicated for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Auto-inflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS) in adults and children older than 12 years and Eylea also called VEGF Trap, is indicated for the treatment of neovascular age-related macular degeneration (wet AMD). Regeneron is headquartered in Tarrytown, NewYork, the US.

Regeneron Pharmaceuticals, Inc. (REGN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharmaceuticals and Healthcare eTrack deals database, and primary and secondary research.